BridgeMD
New treatment option for Essential Tremor
Official title Attention and Eye Movement in Parkinson's Disease
ClinicalTrials.gov ID: NCT06899022
What this study is testing
- What it's testing
- The goal of this observational and interventional study is to understand how therapeutic deep brain stimulation (DBS) affects attention, perception and cognition in participants with Parkinson's disease (PD) and non-PD movement disorders, including essential tremor (ET) and dystonia (DT). The main questions it aims to answer are: Does impaired control of attention and eye movement in PD alter how social cues are perceived and interpreted?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 to 90. Healthy volunteers may be eligible.
You may be able to join if
- All Participants (Aim 1):
- Ability and willingness to provide signed informed consent for this study
- Ability to express perceptual judgments through a button press or mouse- controlled computerized slider
- Age 19 - 90 years
- DBS Participants (Aim 1):
You likely can't join if
- All Participants (Aim 1):
- Corrected visual acuity insufficient to perceptually judge face stimuli
- Inability to understand task instructions or complete task requirements
- DBS Participants (Aim 1): o Insufficient therapeutic control of motor symptoms to engage in tasks requiring button press or use of a mouse to control...
- Healthy Comparison Participants (Aim 1): o History of neurodegenerative disorder
- Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 2):
See the full eligibility criteria
- All Participants (Aim 1):
- Ability and willingness to provide signed informed consent for this study
- Ability to express perceptual judgments through a button press or mouse- controlled computerized slider
- Age 19 - 90 years
- DBS Participants (Aim 1):
- Diagnosis of idiopathic Parkinson's disease (PD), essential tremor (ET) or dystonia (DT).
- Scheduled for new implantation of a therapeutic DBS device targeted to subthalamic nucleus (STN), ventral intermediate nucleus of thalamus (VIM) or internal globus pallidus (GPi)
- Comparison Participants (Aim 1): o Selection by age matching to participants in PD group
- Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 2):
- Ability and willingness to provide signed informed consent for this study
- Ability to express perceptual judgments through a button press or mouse- controlled computerized slider
- Age 19 - 90 years
- Scheduled for awake DBS implantation with clinical micro-electrode recordings (MER)
- Willing and able to engage in tasks during an awake surgical procedure
- Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 3):
- Ability and willingness to provide signed informed consent for this study
- Ability to express perceptual judgments through a button press or mouse- controlled computerized slider
- Age 19 - 90 years
- Willing to undergo acute manipulations of DBS
- Able to tolerate acute changes of DBS
- All Participants (Aim 1):
- Corrected visual acuity insufficient to perceptually judge face stimuli
- Inability to understand task instructions or complete task requirements
- DBS Participants (Aim 1): o Insufficient therapeutic control of motor symptoms to engage in tasks requiring button press or use of a mouse to control a slider
- Healthy Comparison Participants (Aim 1): o History of neurodegenerative disorder
- Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 2):
- Corrected visual acuity insufficient to perceptually judge face stimuli
- Inability to understand task instructions or complete task requirements
- Not undergoing awake DBS implantation
- Uncorrected visual acuity insufficient to perceptually judge face stimuli
- Parkinson's disease (PD), essential tremor (ET) and dystonia (DT) Participants (Aim 3):
- Corrected visual acuity insufficient to perceptually judge face stimuli
- Inability to understand task instructions or complete task requirements
- Failure of DBS to achieve a therapeutic effect on motor symptoms
The study team makes the final eligibility decision.
Where it's taking place
- Omaha, Nebraska, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years to 90 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Omaha, Nebraska, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.